S. Gaine (Dublin, Ireland), M.M. Hoeper (Hanover, Germany), D. O'Callaghan (Dublin, Ireland), A. Reis (Cortegaca, Portugal)
Outcome of candidates for liver transplantation suffering from portopulmonary hypertension
C. Sattler, R. Magnier, H. Bouvaist, X. Jais, E. Artaud Macari, S. Gunther, D. Montani, M. Humbert, G. Simonneau, O. Sitbon, L. Savale (Le Kremlin Bicêtre, Caen, Grenoble, France)
|  |
Prognostic value of right ventricular function in patients with severe pulmonary hypertension associated with respiratory disease
A. Swift, S. Rajaram, D. Capener, C. Hill, C. Davies, J. Hurdman, R. Condliffe, C. Elliot, J. Wild, D. Kiely (Sheffield, United Kingdom)
| |
Long-term effectiveness of transcatheter coil embolotherapy for pulmonary arteriovenous malformation evaluated by 4D dynamic contrast-enhanced 320-slice CT
T. Sugiura, Y. Kasahara, T. Higashide, H. Kasai, N. Yanagawa, S. Sakao, N. Tanabe, K. Tatsumi (Chiba, Japan)
| |
Pulmonary hypertension associated with congenital heart disease (PH-CHD): Results from the ASPIRE registry
S. Ramjug, J. Hurdman, N. Hussain, I. Sabroe, C. Elliot, D. Kiely, R. Condliffe (Sheffield, United Kingdom)
| |
Severe pulmonary hypertension in patients with emphysema but preserved FEV1: Prognosis and response to treatment
M. Brewis, A. Church, A. Peacock, M. Johnson (Glasgow, United Kingdom)
|  |
Baseline hemodynamic predictors of treatment response in pulmonary arterial hypertension
C. Gerges, M. Gerges, Y. Zhou, L. Zhang, M. Lang, I. Lang (Vienna, Austria; Research Triangle Park, United States Of America)
| |
N-terminal pro-brain natriuretic peptide is a useful prognostic marker in patients with pulmonary hypertension and renal insufficiency
L. Harbaum, J. K. Hennigs, E. Griesch, N. Lüneburg, H. J. Baumann, H. Klose (Hamburg, Germany)
| |
The influence of psycho-social factors in the evolution of pulmonary hypertension patients
A. P. Tomuta, N. Bertici, V. Tudorache (Timisoara, Romania)
| |
The role of right heart catheterization prior to initiation of PAH specific therapy
F. Gavilanes, J. L. Alves-Jr., C. Fernandes, C. Jardim, L. Kato, S. Hoette, A. Hovnanian, B. Dias, R. Souza (Sao Paulo, Brazil)
| |
Incident pulmonary arterial hypertension in a Brazilian reference center: Results of a four-year registry
J. L. Alves-Jr., F. Gavilanes, C. Jardim, C. Fernandes, L. Kato, S. Hoette, B. Dias, A. Hovnanian, R. Souza (Sao Paulo, Brazil)
| |
Hemodynamic and clinical relevance of “borderline pulmonary hypertension“
G. Kovacs, A. Avian, V. Foris, M. Tscherner, A. Olschewski, H. Olschewski (Graz, Austria)
| |
Pulmonary vascular reactivity in pulmonary hypertension due to left heart disease
C. Gerges, M. Gerges, M. Lang, J. Mascherbauer, I. Lang (Vienna, Austria)
| |
Characteristics of a stable and satisfactory condition in long term survivors of pulmonary arterial hypertension
M. van de Veerdonk, T. Marcus, F. de Man, H. J. Bogaard, A. Boonstra, N. Westerhof, A. Vonk Noordegraaf (Amsterdam, Netherlands)
| |
Six-minute walk distance targets in elderly IPAH patients – Consideration of predicted values
T. Lange, A. Keller, M. Arzt, M. Pfeifer (Regensburg, Donaustauf, Germany)
| |
Fluid-challenge testing to distinguish PAH from pulmonary hypertension secondary to heart failure
F. P. T. Oosterveer, K. M. Marques, C. P. Allaart, F. S. de Man, H. J. Bogaard, A. C. van Rossum, N. Westerhof, A. Vonk-Noordegraaf, M. L. Handoko (Amsterdam, Netherlands)
| |
Impact of pulmonary arterial hypertension (PAH) on the lives of patients and carers
P. Ferrari, I. Armstrong, R. Aldrighetti, L. Howard, H. Ryftenius, A. Fischer, S. Lombardi, S. Studer, L. Guillevin (Vienna, Austria; Rotherham, London, United Kingdom; Silver Spring, Denver, San Diego, Newark, United States Of America; Stockholm, Sweden; Paris, France)
| |
Tobacco smoke in patients with pulmonary hypertension
S. Keusch, F. Hildenbrand, T. Bollmann, M. Halank, M. Held, R. Kaiser, G. Kovacs, T. Lange, R. Speich, S. Ulrich Somaini (Zurich, Switzerland)
| |
The impact of definition of ILD on WHO group Classification of PH in scleroderma
S. Mathai, M. Gashouta, R. Damico, P. Hassoun (Baltimore, United States Of America)
| |
Inflammatory mediators contribute to pulmonary arterial cell dysfunction in a pulmonary arterial hypertension patient with BMPR2 mutation
L. Vengethasamy, R. Quarck, M. Delcroix (Leuven, Belgium)
| |
Pulmonary veno-occlusive disease (PVOD) induced by chemotherapy: Experience from the French PH network and literature review
S. Günther, M. C. Chaumais, P. Dorfmüller, X. Jaïs, L. Savale, E. Artaud-Macari, F. Perros, S. Cohen-Kaminsky, O. Sitbon, M. Humbert, G. Simmoneau, D. Montani (Le Kremlin Bicêtre, Le Plessis Robinson, France)
| |